Activin/Nodal Signalling and NANOG Orchestrate Human Embryonic Stem Cell Fate Decisions by Controlling the H3K4me3 Chromatin Mark
View / Open Files
Authors
Bertero, Alessandro
Galli, Antonella
Hubner, Nina C
Moreno, Inmaculada
Burks, Deborah
Brown, Stephanie
Pedersen, Roger
Gaffney, Daniel
Mendjan, Sasha
Pauklin, Siim
Publication Date
2015-03-24Journal Title
Genes & Development
ISSN
0890-9369
Publisher
Cold Spring Harbor Laboratory Press
Volume
29
Pages
702-717
Language
English
Type
Article
Metadata
Show full item recordCitation
Bertero, A., Madrigal, P., Galli, A., Hubner, N. C., Moreno, I., Burks, D., Brown, S., et al. (2015). Activin/Nodal Signalling and NANOG Orchestrate Human Embryonic Stem Cell Fate Decisions by Controlling the H3K4me3 Chromatin Mark. Genes & Development, 29 702-717. https://doi.org/10.1101/gad.255984.114
Abstract
Stem cells can self-renew and differentiate into multiple cell types. These characteristics are maintained by the
combination of specific signaling pathways and transcription factors that cooperate to establish a unique epigenetic
state. Despite the broad interest of these mechanisms, the precise molecular controls by which extracellular signals
organize epigenetic marks to confer multipotency remain to be uncovered. Here, we use human embryonic stem
cells (hESCs) to show that the Activin–SMAD2/3 signaling pathway cooperates with the core pluripotency factor
NANOG to recruit the DPY30-COMPASS histone modifiers onto key developmental genes. Functional studies
demonstrate the importance of these interactions for correct histone 3 Lys4 trimethylation and also self-renewal and
differentiation. Finally, genetic studies in mice show that Dpy30 is also necessary to maintain pluripotency in the
pregastrulation embryo, thereby confirming the existence of similar regulations in vivo during early embryonic
development. Our results reveal the mechanisms by which extracellular factors coordinate chromatin status and
cell fate decisions in hESCs.
Keywords
Activin/Nodal, H3K4me3, hESCs, SMAD2/3, DPY30, NANOG
Sponsorship
We thank Andrew Knights for the technical support and helpful
discussion, and the Wellcome-Trust Sanger Institute Microarray
and Next-Generation Sequencing facilities for the technical support.
We also thank the Sanger Institute Mouse Genetics Projects
for mouse production and genotyping. This work was supported
by the European Research Council starting grant Relieve-IMDs
and the Cambridge Hospitals National Institute for Health
Research Biomedical Research Centre (L.V.), a British Heart
Foundation Ph.D. Studentship (A.B.), a Federation of European
Biochemical Societies (FEBS) long-term fellowship and EU Fp7
grant InnovaLIV (S.P.), EU Fp7 grant TissuGEN (S.M.), and Wellcome
Trust grant 098051 (D.G.). A.B. conceived the research, performed
and analyzed the experiments, and wrote the manuscript.
P.M. computationally analyzed ChIP-seq data sets and performed
statistical analyses. N.C.H., S.B., and R.A.P. provided technical
support. A.G. performed embryo dissections and dysmorphology
assessments. I.M. and D.B. performed teratoma assays. D.G. supervised
the bioinformatics data analysis. S.P., S.M., and L.V. conceived
the research and wrote the manuscript.
Funder references
MRC (G1000847)
MRC (G0800784)
Identifiers
External DOI: https://doi.org/10.1101/gad.255984.114
This record's URL: https://www.repository.cam.ac.uk/handle/1810/247918
Rights
Attribution 2.0 UK: England & Wales
Licence URL: http://creativecommons.org/licenses/by/2.0/uk/
Recommended or similar items
The following licence files are associated with this item: